Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-label Trial of KVA12123 [TBS-2025] Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

NCT05708950 is registered in ClinicalTrials.gov with Kineta Inc. as lead sponsor.

NCT NCT05708950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05708950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-label Trial of KVA12123 [TBS-2025] Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Lead sponsor
Kineta Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 3, 2023
Completion date
December 18, 2025
Enrollment
40 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cancer, carcinoma, colo-rectal cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma, solid tumor, thyroid cancer, uterine cancer